Carbohydrate derivatives for use in drug design: Cyclic α(v)-selective RGD peptides

Angewandte Chemie - International Edition

Volumn 39, Issue 15, 2000, Pages 2761-2764

  Lohof, Elisabeth ^a   Planker, Eckart ^a   Mang, Christian ^a   Burkhart, Fred ^a   Dechantsreiter, Michael A ^a   Haubner, Roland ^b   Wester, Hans Jürgen ^b   Schwaiger, Markus ^b   Hölzemann, Günther ^c   Goodman, Simon L ^c   Kessler, Horst ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c MERCK KGAA   (Germany)

Author keywords

Carbohydrates; Drug design; Integrins; Peptidomimetics

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CARBOHYDRATE DERIVATIVE; INTEGRIN;

ARTICLE; BINDING AFFINITY; CELL SURFACE; CONFORMATION; DRUG DESIGN; HYDROPHOBICITY; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

EID: 0034604588     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-3773(20000804)39:15<2761::AID-ANIE2761>3.0.CO;2-9     Document Type: Article

References (31)

1. a) E. Graf von Roedern, H. Kessler, Angew. Chem. 1994, 106, 684-686; Angew. Chem. Int. Ed. Engl. 1994, 33, 687-689;
2. a) E. Graf von Roedern, H. Kessler, Angew. Chem. 1994, 106, 684-686; Angew. Chem. Int. Ed. Engl. 1994, 33, 687-689;
3. b) E. Graf von Roedern, E. Lohof, G. Hessler, M. Hoffmann, H. Kessler, J. Am. Chem. Soc. 1996, 118, 10156-10167;
4. K. Burgess, Y. Feng, Chemtracts: Org. Chem. 1997, 10, 1054-1057.
5. a) M. Aumailley, M. Gurrath, G. Müller, J. Calvete, R. Timpl, H. Kessler, FEBS Lett. 1991, 291, 50-54;
6. b) M. Gurrath, G. Müller, H. Kessler, M. Aumailley, R. Timpl, Eur. J. Biochem. 1992, 210, 911-912;
7. M. Pfaff, K. Tangemann, B. Müller, M. Gurrath, G. Müller, H. Kessler, R. Engel. J. Biol. Chem. 1994, 269, 20233-20238;
8. R. Haubner, R. Gratias, B. Diefenbach, S. Goodman, A. Jonczyk, H. Kessler, J. Am. Chem. Soc. 1996, 118, 7461-7472;
9. e) R. Haubner, D. Finsinger, H. Kessler, Angew. Chem. 1997, 109, 1440-1456; Angew. Chem. Int. Ed. Engl. 1997, 36, 1374-1389.
10. e) R. Haubner, D. Finsinger, H. Kessler, Angew. Chem. 1997, 109, 1440-1456; Angew. Chem. Int. Ed. Engl. 1997, 36, 1374-1389.
11. a) M. Dechantsreiter, Ph.D thesis, Technische Universität München, 1998;
12. b) M. Dechantsreiter, E. Planker, B. Mathä, E. Lohof, G. Hölzemann, A. Jonczryk, S. L. Goodman, H. Kessler, J. Med. Chem. 1999, 42, 3033-3040.
13. a) H. Kessler, B. Diefenbach, D. Finsinger, A. Geyer, M. Gurrath, S. L. Goodman, G. Hölzemann, R. Haubner, A. Jonzcyk, G. Müller, E. Graf von Roedern, J. Wermuth, Lett. Pept. Sci. 1995, 2, 155-160;
14. b) K. C. Nicolaou, J. I. Trujillo, K. Chibale, Tetrahedron 1997, 53, 8751-8778.
15. 3-OH. Fmoc = 9-fluorenyl- methoxycarbonyl. TEMPO = 2.2,6.6-tetramethylpiperidinoxyl radical.
16. 3-OH. Fmoc = 9-fluorenyl- methoxycarbonyl. TEMPO = 2.2,6.6-tetramethylpiperidinoxyl radical.
17. 3-OH. Fmoc = 9-fluorenyl- methoxycarbonyl. TEMPO = 2.2,6.6-tetramethylpiperidinoxyl radical.
18. 3-OH. Fmoc = 9-fluorenyl-methoxycarbonyl. TEMPO = 2.2,6.6-tetramethylpiperidinoxyl radical.
19. A. C. Bach II, J. R. Espina, S. A. Jackson, P. F. W. Stouten, J. L. Duke, S. A. Mousa, W. F. DeGrado, J. Med. Chem. 1996, 118, 293-294.
20. For a review on NMR-spectroscopic conformational analysis and molecular dynamics calculation see: H. Kessler, R. Konat, W. Schmitt, NMR in Drug Design, CRC Series in Analytical Biotechnology, CRC Press, Boca Raton, FL, USA, 1996, pp. 215-244.
21. K. Michael, V. Wittmann, W. König, J. Sandow, H. Kessler, Int. J. Pept. Protein Res. 1996, 48, 59-70.
22. a) 11-14: In this case the cyclic peptide cyclo(-Arg-Gly-Asp-D-Tyr-Lys-) was synthesized first, followed by glycosylation of the amino moiety of the lysine. 11, 12: ref. [1a|; 13-14: ref. [9f] followed by an oxidation as described in ref. [5d];
23. b) F. Burkhart, M. Hoffmann, H. Kessler, Angew. Chem. 1997, 109, 1240-1241; Angew. Chem. Int. Ed. Engl. 1997, 36, 1191-1192;
24. b) F. Burkhart, M. Hoffmann, H. Kessler, Angew. Chem. 1997, 109, 1240-1241; Angew. Chem. Int. Ed. Engl. 1997, 36, 1191-1192;
25. H. Paulsen, S. Peters, T. Bielefeldt, New Compr. Biochem. 1995, 29a, 87-121;
26. M. Hoffmann, F. Burkhart, G. Hessler, H. Kessler. Helv. Chim. Acta 1996, 79, 1519-1532;
27. [9f] with glyoxylic acid, followed by a Fmoc derivatization (Scheme 3);
28. f) L. Petrus, S. Bystricky, T. Sticzay, V. Bilik, Chem. Zvesti 1982, 36, 103-110. (figure presented) Scheme 3. Synthesis of a glycopeptoid building block.
29. The building blocks 15-22 were made as Fmoc derivatives, and were as such used under standard solid-phase conditions with TBTU/HOBt [R. Knorr, A. Trzeciak, W. Bannwarth, D. Gillessen, Tetrahedron Lett. 1989, 30, 1927-1930].
30. a) R. Haubner, H. J. Wester, R. Senekowitsch-Schmidtke, B. Diefenbach, H. Kessler, G. Stöcklin, M. Schwaiger, J. Labelled Compd. Radiopharm. 1998, 40, 853-856;
31. b) R. Haubner, H. J. Wester, R. Senekowitsch-Schmidtke, B. Diefenbach, H. Kessler, G. Stöcklin, M. Schwaiger, J. Nucl. Med. 1999, 40, 1061-1071.